Last reviewed · How we verify
Brinzolamide 1% added to Travoprost 0.004%
Brinzolamide 1% added to Travoprost 0.004% is a Small molecule drug developed by Alcon Research. It is currently FDA-approved.
Brinzolamide 1% added to Travoprost 0.004%, marketed by Alcon Research, is a combination therapy for primary open-angle glaucoma or ocular hypertension. The key composition patent expires in 2028, providing a strong barrier to generic competition until then. The primary risk is the potential loss of exclusivity post-patent expiry, which could lead to increased competition and revenue erosion.
At a glance
| Generic name | Brinzolamide 1% added to Travoprost 0.004% |
|---|---|
| Sponsor | Alcon Research |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves (PHASE4)
- Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension (PHASE4)
- Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z® (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brinzolamide 1% added to Travoprost 0.004% CI brief — competitive landscape report
- Brinzolamide 1% added to Travoprost 0.004% updates RSS · CI watch RSS
- Alcon Research portfolio CI